Symbols / AGIO $34.80 -1.14% Agios Pharmaceuticals, Inc.
AGIO Chart
About
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.04B |
| Enterprise Value | 1.25B | Income | -412.78M | Sales | 54.03M |
| Book/sh | 20.41 | Cash/sh | 14.58 | Dividend Yield | — |
| Payout | 0.00% | Employees | 539 | IPO | — |
| P/E | — | Forward P/E | -6.95 | PEG | — |
| P/S | 37.74 | P/B | 1.70 | P/C | — |
| EV/EBITDA | -2.67 | EV/Sales | 23.10 | Quick Ratio | 10.53 |
| Current Ratio | 11.46 | Debt/Eq | 3.37 | LT Debt/Eq | — |
| EPS (ttm) | -7.12 | EPS next Y | -5.01 | EPS Growth | — |
| Revenue Growth | 86.10% | Earnings | 2026-04-29 | ROA | -19.93% |
| ROE | -30.20% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -6.09% | Profit Margin | 0.00% | Shs Outstand | 58.59M |
| Shs Float | 49.79M | Short Float | 10.64% | Short Ratio | 7.95 |
| Short Interest | — | 52W High | 46.00 | 52W Low | 22.24 |
| Beta | 0.79 | Avg Volume | 929.09K | Volume | 1.06M |
| Target Price | $43.75 | Recom | Buy | Prev Close | $35.20 |
| Price | $34.80 | Change | -1.14% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-06 | main | JP Morgan | Neutral → Neutral | $36 |
| 2026-04-01 | main | Goldman Sachs | Neutral → Neutral | $32 |
| 2026-03-05 | main | Citigroup | Buy → Buy | $46 |
| 2026-02-12 | main | HC Wainwright & Co. | Buy → Buy | $65 |
| 2026-01-06 | main | JP Morgan | Neutral → Neutral | $25 |
| 2025-12-26 | main | Leerink Partners | Outperform → Outperform | $40 |
| 2025-12-24 | main | Truist Securities | Buy → Buy | $38 |
| 2025-12-24 | main | B of A Securities | Buy → Buy | $34 |
| 2025-12-24 | main | HC Wainwright & Co. | Buy → Buy | $62 |
| 2025-11-26 | init | Citigroup | — → Buy | $38 |
| 2025-11-24 | init | Truist Securities | — → Buy | $32 |
| 2025-11-21 | main | JP Morgan | Neutral → Neutral | $20 |
| 2025-11-20 | down | RBC Capital | Outperform → Sector Perform | $28 |
| 2025-11-20 | main | B of A Securities | Buy → Buy | $32 |
| 2025-11-20 | up | Leerink Partners | Market Perform → Outperform | $34 |
| 2025-11-20 | main | Goldman Sachs | Neutral → Neutral | $25 |
| 2025-11-20 | main | HC Wainwright & Co. | Buy → Buy | $48 |
| 2025-09-04 | reit | HC Wainwright & Co. | Buy → Buy | $56 |
| 2025-07-28 | main | Scotiabank | Sector Outperform → Sector Outperform | $65 |
| 2025-07-22 | main | B of A Securities | Buy → Buy | $51 |
- Agios (NASDAQ: AGIO) exec sells shares to cover PSU tax obligations - Stock Titan Mon, 06 Apr 2026 20
- AGIO: JP Morgan Raises Price Target to $36, Maintains Neutral Rating | AGIO Stock News - GuruFocus Mon, 06 Apr 2026 19
- JPMorgan Chase & Co. Raises Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $36.00 - MarketBeat Mon, 06 Apr 2026 18
- Agios (NASDAQ: AGIO) CLO exercises 8,500 PSUs and sells shares for taxes - Stock Titan Mon, 06 Apr 2026 20
- A Look At Agios Pharmaceuticals (AGIO) Valuation As It Pursues Accelerated FDA Approval For Mitapivat - simplywall.st Sat, 04 Apr 2026 16
- Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last? - qz.com Wed, 01 Apr 2026 04
- AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD - Zacks Investment Research Wed, 01 Apr 2026 14
- Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything - The Motley Fool ue, 31 Mar 2026 17
- J.P. Morgan Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Announces Target Price $36 - Moomoo Mon, 06 Apr 2026 14
- Agios (AGIO) CCO vests 8,500 PSUs, sells 3,262 shares for taxes - Stock Titan Mon, 06 Apr 2026 20
- [Form 4] AGIOS PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan Mon, 06 Apr 2026 20
- Agios (NASDAQ: AGIO) CFO exercises PSUs, automatic share sale for taxes - Stock Titan Mon, 06 Apr 2026 20
- Agios will webcast first-quarter results before markets open April 29 - Stock Titan Mon, 06 Apr 2026 11
- Agios (AGIO) CEO settles performance units, sells 19K shares to cover taxes - Stock Titan Mon, 06 Apr 2026 20
- RSU vesting triggers proposed Common Stock sale for AGIO (AGIO) - Stock Titan hu, 02 Apr 2026 20
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
54.03
+48.03%
|
36.50
+36.07%
|
26.82
+88.36%
|
14.24
|
| Operating Revenue |
|
54.03
+48.03%
|
36.50
+36.07%
|
26.82
+88.36%
|
14.24
|
| Cost Of Revenue |
|
6.34
+52.34%
|
4.17
+44.57%
|
2.88
+69.07%
|
1.70
|
| Reconciled Cost Of Revenue |
|
6.34
+52.34%
|
4.17
+44.57%
|
2.88
+69.07%
|
1.70
|
| Gross Profit |
|
47.68
+47.47%
|
32.33
+35.05%
|
23.94
+90.99%
|
12.54
|
| Operating Expense |
|
519.82
+13.48%
|
458.07
+10.26%
|
415.43
+3.45%
|
401.58
|
| Research And Development |
|
339.54
+12.70%
|
301.29
+1.95%
|
295.53
+5.58%
|
279.91
|
| Selling General And Administration |
|
180.28
+14.99%
|
156.78
+30.76%
|
119.90
-1.45%
|
121.67
|
| Total Expenses |
|
526.16
+13.83%
|
462.24
+10.50%
|
418.31
+3.73%
|
403.29
|
| Operating Income |
|
-472.13
-10.90%
|
-425.74
-8.75%
|
-391.49
-0.63%
|
-389.05
|
| Total Operating Income As Reported |
|
-472.13
-10.90%
|
-425.74
-8.75%
|
-391.49
-0.63%
|
-389.05
|
| EBITDA |
|
-466.95
-11.16%
|
-420.08
-9.15%
|
-384.86
-1.15%
|
-380.48
|
| Normalized EBITDA |
|
-466.95
+69.06%
|
-1,509.22
-292.14%
|
-384.86
+25.73%
|
-518.19
|
| Reconciled Depreciation |
|
5.18
-8.42%
|
5.65
-14.65%
|
6.62
-22.66%
|
8.56
|
| EBIT |
|
-472.13
-10.90%
|
-425.74
-8.75%
|
-391.49
-0.63%
|
-389.05
|
| Total Unusual Items |
|
0.00
-100.00%
|
1,089.14
|
0.00
-100.00%
|
137.70
|
| Total Unusual Items Excluding Goodwill |
|
0.00
-100.00%
|
1,089.14
|
0.00
-100.00%
|
137.70
|
| Special Income Charges |
|
0.00
-100.00%
|
1,089.14
|
0.00
-100.00%
|
137.70
|
| Restructuring And Mergern Acquisition |
|
—
|
—
|
—
|
-127.85
|
| Net Income |
|
-412.78
-161.27%
|
673.73
+291.35%
|
-352.09
-51.89%
|
-231.80
|
| Pretax Income |
|
-413.80
-157.63%
|
717.97
+303.92%
|
-352.09
-51.89%
|
-231.80
|
| Net Non Operating Interest Income Expense |
|
56.38
+17.25%
|
48.08
+44.20%
|
33.34
+160.64%
|
12.79
|
| Net Interest Income |
|
56.38
+17.25%
|
48.08
+44.20%
|
33.34
+160.64%
|
12.79
|
| Interest Income Non Operating |
|
56.38
+17.25%
|
48.08
+44.20%
|
33.34
+160.64%
|
12.79
|
| Interest Income |
|
56.38
+17.25%
|
48.08
+44.20%
|
33.34
+160.64%
|
12.79
|
| Other Income Expense |
|
1.96
-99.82%
|
1,095.62
+17994.52%
|
6.05
-95.81%
|
144.45
|
| Other Non Operating Income Expenses |
|
1.96
-69.85%
|
6.49
+7.13%
|
6.05
-10.28%
|
6.75
|
| Gain On Sale Of Business |
|
0.00
-100.00%
|
1,089.14
|
0.00
-100.00%
|
137.70
|
| Tax Provision |
|
-1.02
-102.30%
|
44.24
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
-96.75%
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
-100.00%
|
67.12
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-412.78
-161.27%
|
673.73
+291.35%
|
-352.09
-51.89%
|
-231.80
|
| Net Income From Continuing Operation Net Minority Interest |
|
-412.78
-161.27%
|
673.73
+291.35%
|
-352.09
-51.89%
|
-231.80
|
| Net Income From Continuing And Discontinued Operation |
|
-412.78
-161.27%
|
673.73
+291.35%
|
-352.09
-51.89%
|
-231.80
|
| Net Income Continuous Operations |
|
-412.78
-161.27%
|
673.73
+291.35%
|
-352.09
-51.89%
|
-231.80
|
| Net Income Discontinuous Operations |
|
—
|
—
|
0.00
|
0.00
|
| Normalized Income |
|
-412.78
-18.52%
|
-348.29
+1.08%
|
-352.09
+4.71%
|
-369.50
|
| Net Income Common Stockholders |
|
-412.78
-161.27%
|
673.73
+291.35%
|
-352.09
-51.89%
|
-231.80
|
| Diluted EPS |
|
-7.12
-161.17%
|
11.64
+283.89%
|
-6.33
-49.65%
|
-4.23
|
| Basic EPS |
|
-7.12
-160.03%
|
11.86
+287.36%
|
-6.33
-49.65%
|
-4.23
|
| Basic Average Shares |
|
57.97
+2.05%
|
56.81
+2.08%
|
55.65
+1.57%
|
54.79
|
| Diluted Average Shares |
|
57.97
+0.14%
|
57.89
+4.02%
|
55.65
+1.57%
|
54.79
|
| Diluted NI Availto Com Stockholders |
|
-412.78
-161.27%
|
673.73
+291.35%
|
-352.09
-51.89%
|
-231.80
|
| Total Other Finance Cost |
|
—
|
—
|
—
|
-12.79
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
1,297.22
-22.00%
|
1,663.20
+77.48%
|
937.12
-24.35%
|
1,238.72
|
| Current Assets |
|
942.05
-2.44%
|
965.60
+15.80%
|
833.84
+0.13%
|
832.77
|
| Cash Cash Equivalents And Short Term Investments |
|
854.42
-4.40%
|
893.71
+15.03%
|
776.93
-0.79%
|
783.12
|
| Cash And Cash Equivalents |
|
89.13
+16.90%
|
76.25
-13.56%
|
88.20
-36.66%
|
139.26
|
| Other Short Term Investments |
|
765.29
-6.38%
|
817.46
+18.69%
|
688.72
+6.97%
|
643.86
|
| Receivables |
|
10.58
+157.41%
|
4.11
+46.23%
|
2.81
+27.38%
|
2.21
|
| Accounts Receivable |
|
10.58
+157.41%
|
4.11
+46.23%
|
2.81
+27.38%
|
2.21
|
| Other Receivables |
|
—
|
—
|
—
|
—
|
| Inventory |
|
32.92
+19.21%
|
27.62
+44.77%
|
19.08
+124.63%
|
8.49
|
| Raw Materials |
|
0.09
-1.12%
|
0.09
+74.51%
|
0.05
|
0.00
|
| Work In Process |
|
30.25
+23.44%
|
24.51
+39.51%
|
17.57
+132.69%
|
7.55
|
| Finished Goods |
|
2.58
-14.55%
|
3.02
+107.14%
|
1.46
+54.67%
|
0.94
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Assets Held For Sale Current |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
44.13
+9.87%
|
40.16
+14.69%
|
35.02
-10.10%
|
38.95
|
| Total Non Current Assets |
|
355.17
-49.09%
|
697.60
+575.42%
|
103.28
-74.56%
|
405.95
|
| Net PPE |
|
41.23
-24.43%
|
54.55
-21.83%
|
69.79
-20.80%
|
88.12
|
| Gross PPE |
|
101.34
-8.74%
|
111.05
-8.99%
|
122.02
-11.70%
|
138.19
|
| Accumulated Depreciation |
|
-60.12
-6.40%
|
-56.50
-8.17%
|
-52.23
-4.31%
|
-50.07
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
30.45
-28.98%
|
42.88
-21.19%
|
54.41
-16.46%
|
65.13
|
| Machinery Furniture Equipment |
|
13.06
+6.79%
|
12.23
-0.54%
|
12.29
+2.95%
|
11.94
|
| Construction In Progress |
|
2.75
+206.24%
|
0.90
+47.53%
|
0.61
-7.46%
|
0.66
|
| Other Properties |
|
17.57
+0.22%
|
17.53
+0.55%
|
17.43
-24.80%
|
23.18
|
| Leases |
|
37.52
+0.00%
|
37.52
+0.65%
|
37.28
+0.00%
|
37.28
|
| Investments And Advances |
|
310.01
-51.43%
|
638.32
+2068.58%
|
29.43
-90.62%
|
313.87
|
| Other Non Current Assets |
|
3.93
-16.79%
|
4.72
+16.44%
|
4.06
+2.55%
|
3.96
|
| Total Liabilities Net Minority Interest |
|
104.11
-14.83%
|
122.24
-3.06%
|
126.10
-8.56%
|
137.90
|
| Current Liabilities |
|
82.21
+1.29%
|
81.16
+19.43%
|
67.95
+8.50%
|
62.63
|
| Payables And Accrued Expenses |
|
36.55
+6.13%
|
34.44
+15.90%
|
29.71
-3.71%
|
30.86
|
| Payables |
|
18.36
+4.80%
|
17.51
+79.08%
|
9.78
-47.46%
|
18.62
|
| Accounts Payable |
|
18.36
+10.29%
|
16.64
+70.17%
|
9.78
-47.46%
|
18.62
|
| Current Accrued Expenses |
|
18.20
+7.50%
|
16.93
-15.09%
|
19.93
+62.80%
|
12.24
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
27.26
-8.92%
|
29.93
+28.85%
|
23.23
+28.32%
|
18.11
|
| Total Tax Payable |
|
0.00
-100.00%
|
0.87
|
0.00
|
—
|
| Income Tax Payable |
|
0.00
-100.00%
|
0.87
|
0.00
|
—
|
| Current Debt And Capital Lease Obligation |
|
18.39
+9.60%
|
16.78
+11.81%
|
15.01
+9.84%
|
13.66
|
| Current Capital Lease Obligation |
|
18.39
+9.60%
|
16.78
+11.81%
|
15.01
+9.84%
|
13.66
|
| Total Non Current Liabilities Net Minority Interest |
|
21.91
-46.69%
|
41.09
-29.34%
|
58.14
-22.76%
|
75.28
|
| Liabilities Heldfor Sale Non Current |
|
—
|
—
|
—
|
—
|
| Long Term Debt And Capital Lease Obligation |
|
21.82
-45.74%
|
40.21
-29.45%
|
56.99
-20.85%
|
72.00
|
| Long Term Capital Lease Obligation |
|
21.82
-45.74%
|
40.21
-29.45%
|
56.99
-20.85%
|
72.00
|
| Other Non Current Liabilities |
|
0.09
-89.77%
|
0.88
-23.88%
|
1.16
-64.75%
|
3.28
|
| Stockholders Equity |
|
1,193.11
-22.57%
|
1,540.96
+90.00%
|
811.02
-26.33%
|
1,100.81
|
| Common Stock Equity |
|
1,193.11
-22.57%
|
1,540.96
+90.00%
|
811.02
-26.33%
|
1,100.81
|
| Capital Stock |
|
0.07
+2.74%
|
0.07
+1.39%
|
0.07
+1.41%
|
0.07
|
| Common Stock |
|
0.07
+2.74%
|
0.07
+1.39%
|
0.07
+1.41%
|
0.07
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
74.67
+1.76%
|
73.37
+1.68%
|
72.16
+1.27%
|
71.26
|
| Ordinary Shares Number |
|
58.45
+2.26%
|
57.16
+2.16%
|
55.95
+1.64%
|
55.04
|
| Treasury Shares Number |
|
16.22
+0.00%
|
16.22
+0.00%
|
16.22
+0.00%
|
16.22
|
| Additional Paid In Capital |
|
2,555.04
+2.46%
|
2,493.81
+2.35%
|
2,436.52
+2.10%
|
2,386.32
|
| Retained Earnings |
|
-561.71
-277.18%
|
-148.92
+81.90%
|
-822.65
-74.82%
|
-470.56
|
| Gains Losses Not Affecting Retained Earnings |
|
2.19
+244.47%
|
-1.52
-244.22%
|
-0.44
+96.48%
|
-12.54
|
| Treasury Stock |
|
802.49
+0.00%
|
802.49
+0.00%
|
802.49
+0.00%
|
802.49
|
| Other Equity Adjustments |
|
2.19
+244.47%
|
-1.52
-244.22%
|
-0.44
+96.48%
|
-12.54
|
| Total Equity Gross Minority Interest |
|
1,193.11
-22.57%
|
1,540.96
+90.00%
|
811.02
-26.33%
|
1,100.81
|
| Total Capitalization |
|
1,193.11
-22.57%
|
1,540.96
+90.00%
|
811.02
-26.33%
|
1,100.81
|
| Working Capital |
|
859.85
-2.78%
|
884.44
+15.48%
|
765.88
-0.55%
|
770.14
|
| Invested Capital |
|
1,193.11
-22.57%
|
1,540.96
+90.00%
|
811.02
-26.33%
|
1,100.81
|
| Total Debt |
|
40.21
-29.45%
|
56.99
-20.85%
|
72.00
-15.95%
|
85.66
|
| Capital Lease Obligations |
|
40.21
-29.45%
|
56.99
-20.85%
|
72.00
-15.95%
|
85.66
|
| Net Tangible Assets |
|
1,193.11
-22.57%
|
1,540.96
+90.00%
|
811.02
-26.33%
|
1,100.81
|
| Tangible Book Value |
|
1,193.11
-22.57%
|
1,540.96
+90.00%
|
811.02
-26.33%
|
1,100.81
|
| Available For Sale Securities |
|
310.01
-51.43%
|
638.32
+2068.58%
|
29.43
-90.62%
|
313.87
|
| Investmentin Financial Assets |
|
310.01
-51.43%
|
638.32
+2068.58%
|
29.43
-90.62%
|
313.87
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-372.98
+4.33%
|
-389.84
-31.68%
|
-296.06
+4.34%
|
-309.48
|
| Cash Flow From Continuing Operating Activities |
|
-372.98
+4.33%
|
-389.84
-31.68%
|
-296.06
+4.34%
|
-309.48
|
| Cash From Discontinued Operating Activities |
|
—
|
—
|
0.00
|
0.00
|
| Net Income From Continuing Operations |
|
-412.78
-161.27%
|
673.73
+291.35%
|
-352.09
-51.89%
|
-231.80
|
| Depreciation Amortization Depletion |
|
5.18
-8.42%
|
5.65
-14.65%
|
6.62
-22.66%
|
8.56
|
| Depreciation And Amortization |
|
5.18
-8.42%
|
5.65
-14.65%
|
6.62
-22.66%
|
8.56
|
| Other Non Cash Items |
|
22.43
+102.56%
|
-877.61
-3209.87%
|
28.22
+123.94%
|
-117.86
|
| Stock Based Compensation |
|
52.55
+22.65%
|
42.85
-4.29%
|
44.77
-9.19%
|
49.30
|
| Operating Gains Losses |
|
-0.11
+99.94%
|
-200.21
-38234.48%
|
0.53
+1193.75%
|
-0.05
|
| Gain Loss On Investment Securities |
|
-0.12
+29.34%
|
-0.17
-496.43%
|
-0.03
|
—
|
| Gain Loss On Sale Of PPE |
|
0.01
+112.82%
|
-0.04
-107.05%
|
0.55
+1252.08%
|
-0.05
|
| Change In Working Capital |
|
-33.04
-67.15%
|
-19.77
-3.73%
|
-19.06
-15.97%
|
-16.43
|
| Change In Receivables |
|
-6.47
-397.92%
|
-1.30
-115.07%
|
-0.60
+65.66%
|
-1.76
|
| Changes In Account Receivables |
|
-6.47
-397.92%
|
-1.30
-115.07%
|
-0.60
+72.62%
|
-2.21
|
| Change In Inventory |
|
-5.30
+37.89%
|
-8.54
+19.31%
|
-10.58
-24.63%
|
-8.49
|
| Change In Prepaid Assets |
|
-3.17
+45.41%
|
-5.81
-251.60%
|
3.83
+2277.84%
|
-0.18
|
| Change In Payables And Accrued Expense |
|
-0.53
-104.72%
|
11.17
+173.41%
|
4.08
+124.52%
|
1.82
|
| Change In Accrued Expense |
|
-1.40
-137.95%
|
3.69
-71.18%
|
12.82
+892.64%
|
-1.62
|
| Change In Payable |
|
0.88
-88.29%
|
7.47
+185.56%
|
-8.73
-354.16%
|
3.44
|
| Change In Account Payable |
|
1.75
-73.55%
|
6.60
+175.59%
|
-8.73
-354.16%
|
3.44
|
| Change In Other Current Liabilities |
|
-17.57
-14.96%
|
-15.28
+3.18%
|
-15.79
-101.74%
|
-7.83
|
| Investing Cash Flow |
|
377.18
+3.78%
|
363.44
+51.70%
|
239.57
-1.52%
|
243.26
|
| Cash Flow From Continuing Investing Activities |
|
377.18
+3.78%
|
363.44
+51.70%
|
239.57
-1.52%
|
243.26
|
| Cash From Discontinued Investing Activities |
|
—
|
—
|
0.00
|
0.00
|
| Net PPE Purchase And Sale |
|
-4.32
-162.37%
|
-1.65
-604.60%
|
0.33
+108.32%
|
-3.92
|
| Purchase Of PPE |
|
-4.32
-156.14%
|
-1.69
-68.67%
|
-1.00
+79.53%
|
-4.88
|
| Sale Of PPE |
|
0.00
-100.00%
|
0.04
-96.98%
|
1.32
+37.45%
|
0.96
|
| Capital Expenditure |
|
-14.32
-749.61%
|
-1.69
+90.89%
|
-18.50
-279.00%
|
-4.88
|
| Net Investment Purchase And Sale |
|
391.50
+154.07%
|
-724.05
-382.01%
|
256.75
+122.50%
|
115.39
|
| Purchase Of Investment |
|
-641.76
+58.39%
|
-1,542.43
-269.06%
|
-417.93
+59.46%
|
-1,030.78
|
| Sale Of Investment |
|
1,033.26
+26.26%
|
818.38
+21.30%
|
674.68
-41.14%
|
1,146.17
|
| Net Business Purchase And Sale |
|
0.00
-100.00%
|
1,089.14
|
0.00
-100.00%
|
131.78
|
| Gain Loss On Sale Of Business |
|
0.00
+100.00%
|
-200.00
|
0.00
|
0.00
|
| Net Intangibles Purchase And Sale |
|
-10.00
|
0.00
+100.00%
|
-17.50
|
0.00
|
| Purchase Of Intangibles |
|
-10.00
|
0.00
+100.00%
|
-17.50
|
0.00
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
131.78
|
| Financing Cash Flow |
|
8.68
-39.93%
|
14.44
+165.82%
|
5.43
+131.19%
|
2.35
|
| Cash Flow From Continuing Financing Activities |
|
8.68
-39.93%
|
14.44
+165.82%
|
5.43
+131.19%
|
2.35
|
| Net Issuance Payments Of Debt |
|
—
|
0.00
|
0.00
+100.00%
|
-0.33
|
| Repayment Of Debt |
|
—
|
0.00
|
0.00
+100.00%
|
-0.33
|
| Long Term Debt Payments |
|
—
|
0.00
|
0.00
+100.00%
|
-0.33
|
| Net Long Term Debt Issuance |
|
—
|
0.00
|
0.00
+100.00%
|
-0.33
|
| Net Common Stock Issuance |
|
—
|
—
|
0.00
|
0.00
|
| Common Stock Payments |
|
—
|
—
|
0.00
|
0.00
|
| Repurchase Of Capital Stock |
|
—
|
—
|
0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
8.68
-39.93%
|
14.44
+165.82%
|
5.43
+102.65%
|
2.68
|
| Changes In Cash |
|
12.88
+207.74%
|
-11.96
+76.58%
|
-51.05
+20.06%
|
-63.87
|
| Beginning Cash Position |
|
76.25
-13.56%
|
88.20
-36.66%
|
139.26
-31.44%
|
203.13
|
| End Cash Position |
|
89.13
+16.90%
|
76.25
-13.56%
|
88.20
-36.66%
|
139.26
|
| Free Cash Flow |
|
-387.29
+1.08%
|
-391.53
-24.47%
|
-314.56
-0.06%
|
-314.36
|
| Income Tax Paid Supplemental Data |
|
0.63
-98.54%
|
43.15
+2650.16%
|
1.57
|
0.00
|
| Amortization Of Securities |
|
-7.20
+50.33%
|
-14.49
-186.79%
|
-5.05
-321.62%
|
-1.20
|
| Change In Income Tax Payable |
|
-0.87
-200.00%
|
0.87
|
0.00
|
0.00
|
| Change In Tax Payable |
|
-0.87
-200.00%
|
0.87
|
0.00
|
0.00
|
| Common Stock Issuance |
|
—
|
—
|
—
|
—
|
| Issuance Of Capital Stock |
|
—
|
—
|
—
|
—
|
| Sale Of Business |
|
0.00
-100.00%
|
1,089.14
|
0.00
-100.00%
|
131.78
|
| Cash From Discontinued Financing Activities |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-06 View
- 42026-04-06 View
- 42026-04-06 View
- 42026-04-06 View
- 42026-04-06 View
- 42026-04-06 View
- 42026-03-09 View
- 42026-03-05 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 10-K2026-02-12 View
- 8-K2026-02-12 View
- 8-K2026-01-12 View
- 42026-01-07 View
- 42026-01-02 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|